Iron Homeostasis in Neuron-Glia Interaction

Total Page:16

File Type:pdf, Size:1020Kb

Iron Homeostasis in Neuron-Glia Interaction Iron Homeostasis in Neuron-Glia Interaction Dissertation for the award of the degree Doctor rerum naturalium of the Georg-August University Göttingen within the program Genes and Development of the Georg-August University School of Science (GAUSS) submitted by Tina Kling born in Pforzheim, Germany Göttingen, 2016 Members of the Thesis Committee: Supervisor Prof. Dr. Mikael Simons Max Planck Institute for Experimental Medicine, Göttingen Department of Molecular Neurobiology, Technical University of Munich Second member of the thesis committee Prof. Dr. Christian Klämbt Institut für Neurobiologie, Westfälische Wilhelms Universität, Münster Third member of the thesis committee: Prof. Dr. Jörg Großhans Institut für Entwicklungsbiochemie, Universiätsmedizin, Göttingen Extended Thesis Committee: Prof. Dr. Gregor Bucher, Georg-August University Göttingen Prof. Dr. Ralf Heinrich, Georg-August University Göttingen PD Dr. Hauke Werner, Max Planck Institute for Experimental Medicine, Göttingen Date of Disputation: 19.09.2016 Affidavit I hereby declare that this PhD thesis “Iron Homeostasis in Neuron-Glia Interaction” has been written independently with no other aids or sources than quoted. Tina Kling July 2016 Göttingen, Germany All religions, arts and sciences are branches of the same tree. All these aspirations are directed toward ennobling man's life, lifting it from the sphere of mere physical existence and leading the individual towards freedom. Albert Einstein'Moral Decay', Out of My Later Years (1937, 1995) i Contents Contents .......................................................................................................................................... i List of Figures ............................................................................................................................ vi List of Tables ........................................................................................................................... viii Abbreviations ................................................................................................................................ ix Acknowledgements .................................................................................................................... xiii Summary ..................................................................................................................................... xiv 1 Introduction ............................................................................................................................ 1 1.1 Morphological classes of glia cells ................................................................................... 2 1.1.1 Origin and function of glia cells in the vertebrate system ...................................... 2 1.1.2 Glial cell types in Drosophila .................................................................................... 3 1.1.3 Layout of the larval nervous system of Drosophila ................................................. 5 1.1.4 Development of axonal ensheathment in the PNS ................................................. 6 1.1.5 Comparing axonal ensheathment between Vertebrates and Invertebrates ......... 8 1.2 Modes of neuron-glia interactions .................................................................................. 9 1.2.1 Signaling between neurons and glia ...................................................................... 10 1.2.2 Secreted molecules in the nervous system ........................................................... 10 1.2.3 Metabolic support in the nervous system of Vertebrates and Invertebrates ...... 12 1.3 Iron homeostasis ............................................................................................................ 13 1.3.1 Distribution and storage of iron ............................................................................ 13 1.3.2 Regulation of iron consumption ............................................................................ 15 1.3.3 Iron metabolism in the brain ................................................................................. 16 1.3.4 Iron homeostasis in Drosophila ............................................................................. 17 ii Contents 1.4 Aim of this work ............................................................................................................. 19 2 Material and Methods .......................................................................................................... 20 2.1 Buffer, Media and Solutions .......................................................................................... 20 2.2 Fly Genetics .................................................................................................................... 24 2.2.1 Maintenance and Crossing of Flies ........................................................................ 24 2.2.2 Germline transformation ....................................................................................... 24 2.2.3 Generation of recombinant fly lines ...................................................................... 24 2.2.4 Inhibitor Test of Ferroptosis inhibiting drugs ........................................................ 24 2.2.5 Isolation of primary cells from Drosophila Embryos ............................................. 25 2.2.6 List of fly lines ......................................................................................................... 26 2.3 Immunohistochemistry .................................................................................................. 29 2.3.1 Fixation and antibody staining of Drosophila primary cells .................................. 29 2.3.2 Dissection, fixation and antibody staining of larval nervous system .................... 29 2.3.3 Staining of iron in the larval tissue ........................................................................ 30 2.3.4 List of antibodies used for immunohistochemistry .............................................. 31 2.4 Molecular biology ........................................................................................................... 32 2.4.1 Bacteria strains ...................................................................................................... 32 2.4.2 Plasmids ................................................................................................................. 32 2.4.3 Transformation of DNA .......................................................................................... 33 2.4.4 DNA restriction ...................................................................................................... 33 2.4.5 Mini plasmid purification ....................................................................................... 33 2.4.6 Midi plasmid purification ....................................................................................... 34 2.4.7 Isolation of genomic DNA from tissue ................................................................... 34 2.4.8 Polymerase Chain Reaction ................................................................................... 34 2.4.9 Agarose gel electrophoresis .................................................................................. 35 2.4.10 Molecular Cloning .................................................................................................. 35 2.4.11 Sequencing and primer design .............................................................................. 35 Contents iii 2.5 Biochemical methods ..................................................................................................... 36 2.5.1 Protein extraction from Drosophila larvae ............................................................ 36 2.5.2 SDS polyacrylamide gel electrophoresis ................................................................ 36 2.5.3 Western blot and protein detection ..................................................................... 37 2.5.4 Cell type specific affinity isolation of translating Ribosomes (TRAP) .................... 37 2.5.5 DNAse treatment of RNA ....................................................................................... 39 2.6 Image acquisition, processing and equipment .............................................................. 39 2.6.1 Equipment used for image acquisition .................................................................. 39 2.6.2 Software ................................................................................................................. 40 2.6.3 Statistical analysis .................................................................................................. 41 3 Results ................................................................................................................................... 42 3.1 Screening of conserved glial proteins ............................................................................ 42 3.1.1 Selecting candidates that are necessary in vertebrates and invertebrates ......... 42 3.1.2 Screening concept and results .............................................................................. 42 3.2 p24-1 is crucial for the axon-glial architecture .............................................................. 44 3.2.1 p24-1 expression is essential for glial cells ............................................................ 44 3.2.2 p24-1 inhibition has an strong effect on axons ..................................................... 44 3.2.3 Weak glial defects after p24-1 inhibition in glial
Recommended publications
  • CISD2 (NM 001008388) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC207131L3 CISD2 (NM_001008388) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: CISD2 (NM_001008388) Human Tagged ORF Clone Tag: Myc-DDK Symbol: CISD2 Synonyms: ERIS; Miner1; NAF-1; WFS2; ZCD2 Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC207131). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_001008388 ORF Size: 405 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 CISD2 (NM_001008388) Human Tagged ORF Clone – RC207131L3 OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_001008388.1 RefSeq Size: 5892 bp RefSeq ORF: 408 bp Locus ID: 493856 UniProt ID: Q8N5K1 Protein Families: Transmembrane MW: 15.3 kDa Gene Summary: The protein encoded by this gene is a zinc finger protein that localizes to the endoplasmic reticulum.
    [Show full text]
  • Screening of a Clinically and Biochemically Diagnosed SOD Patient Using Exome Sequencing: a Case Report with a Mutations/Variations Analysis Approach
    The Egyptian Journal of Medical Human Genetics (2016) 17, 131–136 HOSTED BY Ain Shams University The Egyptian Journal of Medical Human Genetics www.ejmhg.eg.net www.sciencedirect.com CASE REPORT Screening of a clinically and biochemically diagnosed SOD patient using exome sequencing: A case report with a mutations/variations analysis approach Mohamad-Reza Aghanoori a,b,1, Ghazaleh Mohammadzadeh Shahriary c,2, Mahdi Safarpour d,3, Ahmad Ebrahimi d,* a Department of Medical Genetics, Shiraz University of Medical Sciences, Shiraz, Iran b Research and Development Division, RoyaBioGene Co., Tehran, Iran c Department of Genetics, Shahid Chamran University of Ahvaz, Ahvaz, Iran d Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran Received 12 May 2015; accepted 15 June 2015 Available online 22 July 2015 KEYWORDS Abstract Background: Sulfite oxidase deficiency (SOD) is a rare neurometabolic inherited disor- Sulfite oxidase deficiency; der causing severe delay in developmental stages and premature death. The disease follows an auto- Case report; somal recessive pattern of inheritance and causes deficiency in the activity of sulfite oxidase, an Exome sequencing enzyme that normally catalyzes conversion of sulfite to sulfate. Aim of the study: SOD is an underdiagnosed disorder and its diagnosis can be difficult in young infants as early clinical features and neuroimaging changes may imitate some common diseases. Since the prognosis of the disease is poor, using exome sequencing as a powerful and efficient strat- egy for identifying the genes underlying rare mendelian disorders can provide important knowledge about early diagnosis, disease mechanisms, biological pathways, and potential therapeutic targets.
    [Show full text]
  • Cytotoxic Effects and Changes in Gene Expression Profile
    Toxicology in Vitro 34 (2016) 309–320 Contents lists available at ScienceDirect Toxicology in Vitro journal homepage: www.elsevier.com/locate/toxinvit Fusarium mycotoxin enniatin B: Cytotoxic effects and changes in gene expression profile Martina Jonsson a,⁎,MarikaJestoib, Minna Anthoni a, Annikki Welling a, Iida Loivamaa a, Ville Hallikainen c, Matti Kankainen d, Erik Lysøe e, Pertti Koivisto a, Kimmo Peltonen a,f a Chemistry and Toxicology Research Unit, Finnish Food Safety Authority (Evira), Mustialankatu 3, FI-00790 Helsinki, Finland b Product Safety Unit, Finnish Food Safety Authority (Evira), Mustialankatu 3, FI-00790 Helsinki, c The Finnish Forest Research Institute, Rovaniemi Unit, P.O. Box 16, FI-96301 Rovaniemi, Finland d Institute for Molecular Medicine Finland (FIMM), University of Helsinki, P.O. Box 20, FI-00014, Finland e Plant Health and Biotechnology, Norwegian Institute of Bioeconomy, Høyskoleveien 7, NO -1430 Ås, Norway f Finnish Safety and Chemicals Agency (Tukes), Opastinsilta 12 B, FI-00521 Helsinki, Finland article info abstract Article history: The mycotoxin enniatin B, a cyclic hexadepsipeptide produced by the plant pathogen Fusarium,isprevalentin Received 3 December 2015 grains and grain-based products in different geographical areas. Although enniatins have not been associated Received in revised form 5 April 2016 with toxic outbreaks, they have caused toxicity in vitro in several cell lines. In this study, the cytotoxic effects Accepted 28 April 2016 of enniatin B were assessed in relation to cellular energy metabolism, cell proliferation, and the induction of ap- Available online 6 May 2016 optosis in Balb 3T3 and HepG2 cells. The mechanism of toxicity was examined by means of whole genome ex- fi Keywords: pression pro ling of exposed rat primary hepatocytes.
    [Show full text]
  • Assessment of Genetic Mutations in WFS1 & CISD2 in Wolfram
    Online Journal of Neurology and L UPINE PUBLISHERS Brain Disorders Open Access DOI: 10.32474/OJNBD.2018.01.000104 ISSN: 2637-6628 Research Article Assessment of Genetic Mutations in WFS1 & CISD2 in Wolfram Syndrome Human Shahin Asadi*, Mahsa Jamali, Hamideh Mohammadzadeh and Mahya Fattahi Director of the Division of Medical Genetics and Molecular Research, Iran Received: January 25, 2018; Published: February 15, 2018 *Corresponding author: Shahin Asadi, Molecular Genetics Iran Tabriz, Director of the Division of Medical Genetics and Molecular Research, Iran Abstract In this study we have analyzed 30 people. 10 patients Wolfram syndrome and 20 persons control group. The genes WFS1 and CISD2, analyzed in terms of genetic mutations made. In this study, people who have genetic mutations were targeted, with nervous disorders Wolfram syndrome. In fact, of all people with Wolfram syndrome. 10 patients Wolfram syndrome had a genetic mutation in the genes WFS1 and CISD2 Wolfram syndrome. Any genetic mutations in the target genes control group did not show. Keywords: Genetic study; Wolfram syndrome; Mutations The gene WFS1 and CISD2; RT-PCR. Generalizations of Wolfram Syndrome urinary tract, decreased testosterone levels in men (hypogonadism), Wolfram syndrome is a genetic disorder that affects many body Nervous or psychiatric disorders [1]. systems. The specific characteristics of Wolfram syndrome include: mellitus) and progressive vision loss due to degeneration of the syndrome, which is commonly diagnosed at about 6 years of age. high blood sugar levels due to insulin hormone deficiency (diabetes Diabetes mellitus is usually the first symptom of Wolfram nerves that transports visual information from the eye to the brain Almost all people with Wolfram syndrome who have diabetes need (vision atrophy).
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Human Robo3 Blocking Peptide (CDBP2568) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Human Robo3 blocking peptide (CDBP2568) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Product Overview Blocking/Immunizing peptide for anti-ROBO3/RIG1 (internal) antibody Antigen Description This gene is a member of the Roundabout (ROBO) gene family that controls neurite outgrowth, growth cone guidance, and axon fasciculation. ROBO proteins are a subfamily of the immunoglobulin transmembrane receptor superfamily. SLIT proteins 1-3, a family of secreted chemorepellants, are ligands for ROBO proteins and SLIT/ROBO interactions regulate myogenesis, leukocyte migration, kidney morphogenesis, angiogenesis, and vasculogenesis in addition to neurogenesis. This gene, ROBO3, has a putative extracellular domain with five immunoglobulin (Ig)-like loops and three fibronectin (Fn) type III motifs, a transmembrane segment, and a cytoplasmic tail with three conserved signaling motifs: CC0, CC2, and CC3 (CC for conserved cytoplasmic). Unlike other ROBO family members, ROBO3 lacks motif CC1. The ROBO3 gene regulates axonal navigation at the ventral midline of the neural tube. In mouse, loss of Robo3 results in a complete failure of commissural axons to cross the midline throughout the spinal cord and the hindbrain. Mutations ROBO3 result in horizontal gaze palsy with progressive scoliosis (HGPPS); an autosomal recessive disorder characterized by congenital absence of horizontal gaze, progressive scoliosis, and failure of the corticospinal and somatosensory axon tracts to cross the midline in the medulla.
    [Show full text]
  • Wolfram Syndrome
    Wolfram syndrome Description Wolfram syndrome is a condition that affects many of the body's systems. The hallmark features of Wolfram syndrome are high blood sugar levels resulting from a shortage of the hormone insulin (diabetes mellitus) and progressive vision loss due to degeneration of the nerves that carry information from the eyes to the brain (optic atrophy). People with Wolfram syndrome often also have pituitary gland dysfunction that results in the excretion of excessive amounts of urine (diabetes insipidus), hearing loss caused by changes in the inner ear (sensorineural deafness), urinary tract problems, reduced amounts of the sex hormone testosterone in males (hypogonadism), or neurological or psychiatric disorders. Diabetes mellitus is typically the first symptom of Wolfram syndrome, usually diagnosed around age 6. Nearly everyone with Wolfram syndrome who develops diabetes mellitus requires insulin replacement therapy. Optic atrophy is often the next symptom to appear, usually around age 11. The first signs of optic atrophy are loss of color vision and side ( peripheral) vision. Over time, the vision problems get worse, and people with optic atrophy are usually blind within approximately 8 years after signs of optic atrophy first begin. In diabetes insipidus, the pituitary gland, which is located at the base of the brain, does not function normally. This abnormality disrupts the release of a hormone called vasopressin, which helps control the body's water balance and urine production. Approximately 70 percent of people with Wolfram syndrome have diabetes insipidus. Pituitary gland dysfunction can also cause hypogonadism in males. The lack of testosterone that occurs with hypogonadism affects growth and sexual development.
    [Show full text]
  • UNIVERSITY of CALIFORNIA, SAN DIEGO Biochemical and Structural
    UNIVERSITY OF CALIFORNIA, SAN DIEGO Biochemical and Structural Characterization of the NEET Protein Family and their Role in Iron Homeostasis and Disease A Dissertation submitted in partial satisfaction of the requirements of the degree Doctor of Philosophy in Chemistry by Colin Harrison Lipper Committee in charge: Professor Patricia A. Jennings, Chair Professor Joseph A. Adams Professor Michael Galperin Professor Stanley J. Opella Professor Navtej Toor 2017 Copyright Colin Harrison Lipper, 2017 All rights reserved The dissertation of Colin Harrison Lipper is approved, and it is acceptable in quality and form for publication on microfilm and electronically: Chair UNIVERSITY OF CALIFORNIA, SAN DIEGO 2017 iii DEDICATION To my wife Hope. Thank you for all of your love and support. I could not have done this without you. iv TABLE OF CONTENTS Signature Page ................................................................................................ iii Dedication ....................................................................................................... iv Table of Contents ............................................................................................. v List of Figures .................................................................................................. vi List of Tables ................................................................................................... ix List of Abbreviations ..............................................................................……... x Acknowledgements .......................................................................................
    [Show full text]
  • The NFB Antagonist CDGSH Iron-Sulfur Domain 2 Is a Promising
    International Journal of Molecular Sciences Review The NFκB Antagonist CDGSH Iron-Sulfur Domain 2 Is a Promising Target for the Treatment of Neurodegenerative Diseases Woon-Man Kung 1 and Muh-Shi Lin 2,3,4,5,* 1 Department of Exercise and Health Promotion, College of Kinesiology and Health, Chinese Culture University, Taipei 11114, Taiwan; [email protected] 2 Division of Neurosurgery, Department of Surgery, Kuang Tien General Hospital, Taichung 43303, Taiwan 3 Department of Biotechnology and Animal Science, College of Bioresources, National Ilan University, Yilan 26047, Taiwan 4 Department of Biotechnology, College of Medical and Health Care, Hung Kuang University, Taichung 43302, Taiwan 5 Department of Health Business Administration, College of Medical and Health Care, Hung Kuang University, Taichung 43302, Taiwan * Correspondence: [email protected]; Tel.: +886-4-2665-1900 Abstract: Proinflammatory response and mitochondrial dysfunction are related to the pathogenesis of neurodegenerative diseases (NDs). Nuclear factor κB (NFκB) activation has been shown to exaggerate proinflammation and mitochondrial dysfunction, which underlies NDs. CDGSH iron-sulfur domain 2 (CISD2) has been shown to be associated with peroxisome proliferator-activated receptor-β (PPAR- β) to compete for NFκB and antagonize the two aforementioned NFκB-provoked pathogeneses. Therefore, CISD2-based strategies hold promise in the treatment of NDs. CISD2 protein belongs to the human NEET protein family and is encoded by the CISD2 gene (located at 4q24 in humans). In CISD2, the [2Fe-2S] cluster, through coordinates of 3-cysteine-1-histidine on the CDGSH domain, acts as a homeostasis regulator under environmental stress through the transfer of electrons or iron-sulfur clusters.
    [Show full text]
  • Bioinformatics Tools for the Analysis of Gene-Phenotype Relationships Coupled with a Next Generation Chip-Sequencing Data Processing Pipeline
    Bioinformatics Tools for the Analysis of Gene-Phenotype Relationships Coupled with a Next Generation ChIP-Sequencing Data Processing Pipeline Erinija Pranckeviciene Thesis submitted to the Faculty of Graduate and Postdoctoral Studies in partial fulfillment of the requirements for the Doctorate in Philosophy degree in Cellular and Molecular Medicine Department of Cellular and Molecular Medicine Faculty of Medicine University of Ottawa c Erinija Pranckeviciene, Ottawa, Canada, 2015 Abstract The rapidly advancing high-throughput and next generation sequencing technologies facilitate deeper insights into the molecular mechanisms underlying the expression of phenotypes in living organisms. Experimental data and scientific publications following this technological advance- ment have rapidly accumulated in public databases. Meaningful analysis of currently avail- able data in genomic databases requires sophisticated computational tools and algorithms, and presents considerable challenges to molecular biologists without specialized training in bioinfor- matics. To study their phenotype of interest molecular biologists must prioritize large lists of poorly characterized genes generated in high-throughput experiments. To date, prioritization tools have primarily been designed to work with phenotypes of human diseases as defined by the genes known to be associated with those diseases. There is therefore a need for more prioritiza- tion tools for phenotypes which are not related with diseases generally or diseases with which no genes have yet been associated in particular. Chromatin immunoprecipitation followed by next generation sequencing (ChIP-Seq) is a method of choice to study the gene regulation processes responsible for the expression of cellular phenotypes. Among publicly available computational pipelines for the processing of ChIP-Seq data, there is a lack of tools for the downstream analysis of composite motifs and preferred binding distances of the DNA binding proteins.
    [Show full text]
  • Browsing Genes and Genomes with Ensembl
    Browsing Genes and Genomes with Ensembl Ensembl Workshop University of Cambridge 3rd September 2013 www.ensembl.org Denise Carvalho-Silva Ensembl Outreach Notes: This workshop is based on Ensembl release 72 (June 2013). 1) Presentation slides The pdf file of the talks presented in this workshop is available in the link below: http://www.ebi.ac.uk/~denise/naturimmun 2) Course booklet A diGital Copy of this course booklet can be found below: http://www.ebi.ac.uk/~denise/coursebooklet.pdf 3) Answers The answers to the exercises in this course booklet can be found below: http://www.ebi.ac.uk/~denise/answers 2 TABLE OF CONTENTS OVERVIEW ...................................................................................................... 4 INTRODUCTION TO ENSEMBL .................................................................. 5 BROWSER WALKTHROUGH .................................................................... 14 EXERCISES .................................................................................................... 38 BROWSER ..................................................................................................... 38 BIOMART ...................................................................................................... 41 VARIATION ................................................................................................... 48 COMPARATIVE GENOMICS ...................................................................... 50 REGULATION ..............................................................................................
    [Show full text]
  • Mitochondrial Sequestration of GABA by Aralar in Drosophila Cyfip Haploinsufficiency Causes Deficits in Social Group Behavior
    Kanellopoulos et al. Main text Mitochondrial sequestration of GABA by Aralar in Drosophila Cyfip haploinsufficiency causes deficits in social group behavior Alexandros K. Kanellopoulos1, Vittoria Mariano1,2, Marco Spinazzi2,3, Young Jae Woo4,5, Colin McLean6, Ulrike Pech7, Ka Wan Li8, J. Douglas Armstrong6, Angela Giangrande9, Patrick Callaerts2, August B. Smit8, Brett S. Abrahams4,10, Andre Fiala7, Tilmann Achsel1 and Claudia Bagni1,11,* 1University of Lausanne, Department of Fundamental Neurosciences, Lausanne, Switzerland 2KU Leuven, Department of Neurosciences, Leuven, 3000, Belgium 3VIB Center for Brain & Disease Research, Leuven, 3000, Belgium 4Department of Genetics, Albert Einstein College of Medicine, Bronx, New York; 5Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA 6University of Edinburgh, School of Informatics, Edinburgh, UK 7Georg-August-University Göttingen, Department of Molecular Neurobiology of Behaviour, Göttingen, Germany 8Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, VU University Amsterdam, Amsterdam, The Netherlands 9Centre National de la Recherche Scientifique, UMR7104, Institut National de la Sante´ et de la Recherche Medicale, Universite´ de Strasbourg, Illkirch, France 10Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, USA 11University of Rome Tor Vergata, Department of Biomedicine and Prevention, Rome, Italy *Corresponding author: Claudia Bagni, Ph.D. e-mail: [email protected]; [email protected]; Tel (1): +41-216925120; Tel (2): +39-0672596063 Running title: Mitochondria regulate GABA availability and behavior Keywords: Mitochondrial activity, mitochondrial membrane potential, GABA, social group behavior, Aralar, Drosophila, CYFIP1, autism, schizophrenia. SUMMARY Social impairment is frequently associated with mitochondrial dysfunction and altered neurotransmission.
    [Show full text]